Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03491397 · ClinicalTrials.gov registry record · NA
Genicular Artery Embolization for the Treatment of Knee Osteoarthritis
A NA study, sponsored by Siddharth Padia, MD.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT03491397 is a NA study that has completed, run by Siddharth Padia, MD. The registered enrollment target is 40 participants.
The verdict
NCT03491397, a NA study, has completed, sponsored by Siddharth Padia, MD.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to examine whether Embozene treatment of the genicular artery is a safe and effective way to treat arthritic knee pain. Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain. One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain. The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain. This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.
Interventions
- DEVICE Embozene MicroSpheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-02-10 |
| Est. Completion | 2021-10-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03491397
The ClinicalTrials.gov registry entry for NCT03491397 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Siddharth Padia, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Embozene MicroSpheres is the first listed.
NCT03491397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03491397 about?
NCT03491397 is a clinical study titled "Genicular Artery Embolization for the Treatment of Knee Osteoarthritis". The purpose of this clinical research study is to examine whether Embozene treatment of the genicular artery is a safe and effective way to treat arthritic knee pain. Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and ar...
What is the current status of trial NCT03491397?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2019-02-10. Estimated completion is 2021-10-29.
What interventions are being tested in trial NCT03491397?
The interventions under investigation include: Embozene MicroSpheres (DEVICE).
Who is sponsoring clinical trial NCT03491397?
This trial is sponsored by Siddharth Padia, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.